SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001346302-21-000040
Filing Date
2021-05-06
Accepted
2021-05-06 16:04:00
Documents
16
Period of Report
2021-05-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xers-20210503.htm   iXBRL 8-K 39751
2 EX-99.1 expandedsvboxforddebtmay20.htm EX-99.1 12406
8 image_01.jpg GRAPHIC 18612
  Complete submission text file 0001346302-21-000040.txt   258857

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xers-20210503.xsd EX-101.SCH 2408
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT xers-20210503_cal.xml EX-101.CAL 708
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT xers-20210503_def.xml EX-101.DEF 15449
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xers-20210503_lab.xml EX-101.LAB 29866
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xers-20210503_pre.xml EX-101.PRE 16118
9 EXTRACTED XBRL INSTANCE DOCUMENT xers-20210503_htm.xml XML 11514
Mailing Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601
Business Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601 844-445-5704
XERIS PHARMACEUTICALS INC (Filer) CIK: 0001346302 (see all company filings)

IRS No.: 203352427 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38536 | Film No.: 21897635
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences